Tensive raises €500,000 from Invitalia and Unicredit

Invitalia, through its Italia Venture I fund, and Unicredit participated in the round, each providing a €250,000 equity ticket to support the transaction, according to press reports.

The round raised the company's total amount of funding to €1.9m. The company claims the funding will be used to further develop its product, which is in pre-clinical development phase and is yet to be tested in human patients.

Italia Venture I fund, which has recently secured a €5m capital commitment from Fondazione di Sardegna and reached a total capital commitment of €65m, expects to reach its €100m target in September 2017. The vehicle counts Italy's Cassa Depositi e Presiti, Cisco and Metec among its investors.

Company
Based in Milan, Tensive is a biomedical business founded in 2012 following a spin-off from Filarete Fundation. The company develops biodegradable prostheses, which offer natural blood vessels and adipose tissue reconstruction. The company's flagship product, Regenera, is used in breast reconstruction.

People
Invitalia Ventures – Salvo Mizzi (CEO).
Tensive – Alberto Cantaluppi (chair); Gianfranco Bellezza (CEO).

Advisers
Equity (Unicredit) – Legance Studio Legale Associato (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Italy
• Venture